Huang et al. demonstrated that sorafenib upregulates ABCC5 through the PI3K/Akt/Nrf2 pathway, which inhibits lipid peroxidation-mediated ferroptosis and promotes cancer progression, leading to acquired sorafenib resistance in human HCC cells. This evidence concerns the gene ABCC5 and hepatocellular carcinoma.